This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Presentation

Oral formulations of colestyramine resin.

Drugs List

  • colestyramine 4g oral powder sachets
  • colestyramine 4g oral powder sugar-free
  • QUESTRAN 4g oral powder sachets
  • QUESTRAN LIGHT 4g sachets
  • Therapeutic Indications

    Uses

    Diarrhoea (after vagotomy)
    Diarrhoea (from ileal disease or resection)
    Hyperlipidaemia type 2
    Management of radiation induced diarrhoea
    Pruritus due to liver disease
    Treatment of primary hypercholesterolaemia resistant to diet

    Dosage

    Adults

    Primary prevention of coronary heart disease, cholesterol reduction
    Colestyramine dosage regime should be gradually introduced over a three to four week period to reduce the risk of gastrointestinal upsets. The dose is given either as a single daily dose or divided doses up to four times daily, according to patient acceptability and dosage requirements. The final dose is usually in the range of three to six sachets per day and may be increased up to nine sachets a day if necessary.

    The following schedule can be used to guide the phasing in of colestyramine:
    Initiate treatment at 4g daily and increase in steps of 4g weekly, to between 12g and 24g daily given in one to four divided doses. The maximum dose is 36g daily.

    Relief of diarrhoea
    Same as above, although dose reduction may be possible.

    Relief of pruritus
    4g to 8g daily.

    Children

    To minimise potential gastrointestinal side effects, it is desirable to begin all therapy in children with one dose of colestyramine daily.

    Children aged 12 to 18 years
    (See Dosage; Adult)

    Children aged 6 to 12 years
    Initial dose = (Bodyweight in kg x Adult dose) divided by 70.
    Subsequent dosage adjustment may be necessary where clinically indicated.

    The following alternative dosing schedule may be suitable:

    Familial hypercholesterolaemia
    Children aged 12 to 18 years: Initial dose: 4g daily. Increase in steps of 4g weekly, to between 12g and 24g daily given in one to four divided doses. The maximum dose is 36g daily.
    Children aged 6 to 12 years: Initial dose: 4g daily. Increase up to 4g three times daily titrated to response.

    Pruritus; Diarrhoea
    Children aged 12 to 18 years: 4g to 8g once daily (up to a maximum of 36g daily).
    Children aged 6 to 12 years: 4g once daily (up to a maximum of 24g daily).
    Children aged 1 to 6 years: 2g once daily (up to a maximum of 18g daily).
    Children aged 1 month to 1 year: 1g once daily (up to a maximum of 9g daily).
    If diarrhoea does not resolve within three days, an alternative agent should be considered.
    Add powder to a suitable liquid and titrate dose according to response. The total daily dose may alternatively be given in two to four divided doses

    Contraindications

    Neonates under 1 month
    Complete biliary obstruction

    Precautions and Warnings

    Children aged 1 month to 6 years
    Breastfeeding
    Glucose-galactose malabsorption syndrome
    Hereditary fructose intolerance
    Phenylketonuria
    Pregnancy

    Some formulations contain aspartame - caution in phenylketonuria
    Folate supplementation may be necessary in some patients
    Contains polyethylene glycol
    Some formulations contain sucrose
    Administer concurrent drugs 1 hour before or 4-6 hrs after this medication
    Bile acid malabsorption diarrhoea: change therapy if no response in 3 days
    Chronic use may cause increased bleeding tendency due to vit K deficiency
    Doses > 24g/day of colestyramine may interfere with normal fat metabolism
    Prolonged use may cause hyperchloremic acidosis especially in children
    Supplements of fat-soluble vitamins A,D,E and K may be required
    This product should not be taken in the dry form-mix with fluid as directed

    Reduction of serum folate concentrations have been reported in children with familial hypercholesterolaemia.

    Vitamin K deficiency will usually respond to parenteral vitamin K administration promptly. Recurrences can be prevented by oral administration of vitamin K.

    Pregnancy and Lactation

    Pregnancy

    Colestyramine should be used with caution during pregnancy.

    The safety of colestyramine in pregnancy has not been established and the possibility that interference may occur with the absorption of fat-soluble vitamins should be considered. Because this may be detrimental to the foetus, colestyramine should not be given during pregnancy unless considered essential.

    Lactation

    Colestyramine should be used with caution during breastfeeding.

    The safety of colestyramine in breastfeeding has not been established and the possibility that interference may occur with the absorption of fat-soluble vitamins should be considered.

    Side Effects

    Abdominal discomfort
    Anorexia
    Constipation
    Diarrhoea
    Dyspepsia
    Flatulence
    Heartburn
    Hyperchloraemic acidosis
    Increased bleeding tendency
    Interference with absorption of fat soluble vitamins
    Intestinal obstruction
    Nausea
    Night blindness
    Osteoporosis
    Perianal irritation
    Rash
    Skin irritation
    Steatorrhoea
    Tongue irritation
    Vomiting

    Overdosage

    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

    Further Information

    Last Full Review Date: May 2016

    Reference Sources

    Summary of Product Characteristics: Questran 4g/sachet Powder for Oral Suspension. Neon Healthcare Limited. Revised February 2022.

    Summary of Product Characteristics: Questran Light. Bristol-Myers Squibb Holdings Ltd. Revised January 2014.

    NICE Evidence Services Available at: www.nice.org.uk Last accessed: 12 July 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.